DermBiont

Chromaderm develops a topical inhibitor of melanin production as a first-in-class therapy for skin brightening, melasma, and other skin diseases associated with increased melanin production.

SeylanMED is a biotechnology company focused on developing targeted therapies for Seborrheic Keratosis (SK). Their primary goal is to create a topical Akt inhibitor, which would be the first of its kind treatment for SK. The company's lead drug candidate, SM-020, represents a novel molecularly-targeted approach to treating this condition. SeylanMED has secured funding from angel investors, including board-certified dermatologists, and is currently operating in stealth mode.